Mitochondria first. Peptides second.

MOTS-c

Mitochondrial research peptide studied as a metabolic signal. No ISSCA dose table.

Mitochondrial-derived peptide (12S rRNA ORF)

Research peptide. Not FDA-approved. Not in ISSCA Volume 1 core peptide chapters as a dosed protocol. This desk will not invent a clinic dose.

A 16-amino-acid peptide encoded in the mitochondrial genome. In published research it is studied as a metabolic signal (AMPK-related, exercise-mimetic, insulin-sensitivity literature) rather than as a tissue-repair peptide like BPC-157. ISSCA’s longevity chapter treats mitochondrial support as a multiplier of repair signaling — not as a license to stack unlisted injectables.

Cycle / washout. No ISSCA cycle. Do not run continuous unmonitored courses.

• A substitute for zone-2 training, sleep, or protein
• Self-directed fat-loss stacking on top of a GLP-1
• Any invented milligram protocol from a chatbot

Sources: Vol 2 Ch.15 (mitochondrial support as longevity multiplier — conceptual) · Research-literature framing only

SS-31 (elamipretide)

Cardiolipin-targeted mitochondrial research (elamipretide). Literacy, not a starter stack.

Mitochondrial inner-membrane tetrapeptide

Investigational (elamipretide has been studied in clinical trials for mitochondrial and cardiac indications). Not an ISSCA core protocol peptide in this library. Not a catalog ‘pin tonight’ compound.

A small tetrapeptide that associates with cardiolipin on the inner mitochondrial membrane. Research focus: electron-transport efficiency, ROS at complex I/III, and tissues with high ATP demand (heart, kidney, muscle). This is mitochondrial medicine literature — distinct from gastric repair peptides.

Cycle / washout. No ISSCA cycle.

• DIY ‘mito stack’ with MOTS-c + NAD+ + SS-31
• Replacing indicated heart-failure or mitochondrial-disease care

Sources: Vol 2 Ch.15 conceptual mitochondrial multiplier · Investigational / trial-class — not ISSCA-dosed

Humanin

Mitochondrial-derived peptide in magazine longevity/immune stacks. Textbook has no milligram table.

Mitochondrial-derived cytoprotective peptide

Research. Volume 1–2 textbooks in this library have no milligram table. ISSCA peptides magazine faculty published a range.

A mitochondrial-derived peptide discussed for cytoprotection, metabolic stress, and healthspan literacy. Grouped with MOTS-c as an MDP. Magazine longevity and immune articles include it in faculty stacks.

Cycle / washout. Magazine longevity: during the 10–20 day Epitalon window. Immune article: up to 12 weeks then 1 month off.

• Anti-aging injections off a chat window

Sources: ISSCA Peptides Magazine pp.10, 26 · Vol 2 Ch.15 conceptual MDP framing

NAD+ / NAD-support (not a peptide)

Cofactor / sirtuin talk, not a peptide protocol. Sleep and training sit underneath.

Redox cofactor — adjacent to mitochondrial peptides

NAD+ is a cofactor, not a signaling peptide. IV NAD clinics and research vials are not ISSCA peptide-protocol cards. Oral NR/NMN supplements are a different regulatory bucket than injectable peptides.

ISSCA Volume 2 frames mitochondrial support as a longevity multiplier around repair, immune quieting, and endocrine preservation — not as an IV cocktail. NAD biology (sirtuins, PARPs, redox) is real; this desk will not turn that into an infusion recipe.

Cycle / washout. Foundations are ongoing. Peptide stacks still wash out (Vol 2: 4–6 weeks typical).

• Chat-designed NAD IV drip
• Stacking NAD + GH + GLP-1 because a forum said so

Sources: Vol 2 Ch.15

Tesamorelin (visceral fat / GHRH analogue)

Labeled GHRH analogue for visceral fat in a specific population — prescription.

FDA-labeled GHRH analogue — metabolic / VAT

Tesamorelin is FDA-approved for HIV-associated lipodystrophy (visceral adipose reduction). ISSCA lists 2 mg nightly in the Volume 1 arsenal for visceral fat / metabolic enhancement. Labeled use is a prescription, not a research vial.

A stabilized GHRH analogue. Distinct from CJC-1295/ipamorelin compounding. The labeled indication is reduction of excess abdominal fat in HIV lipodystrophy. Off-label metabolic use is clinician territory.

Cycle / washout. Labeled courses are prescriber-directed. Secretagogue cycling rules in Ch.8–9 do not automatically map onto branded tesamorelin.

• Active malignancy (IGF-1 theory, same GH-axis caution)
• Pregnancy
• Uncontrolled diabetes without a prescriber

Sources: Vol 1 Ch.1 p.12

Longevity Class I — quiet inflammation

• BPC-157 250–500 mcg/day
• KPV 200 mcg/day

Duration. 6 weeks

First longevity move. No GH or immune stimulation at this stage.

Vol 2 Ch.15 p.117

Longevity Class II — repair + endocrine preservation

• BPC-157 500 mcg/day
• TB-500 2 mg/week
• CJC-1295 100 mcg pre-sleep
• Ipamorelin 100 mcg pre-sleep

Duration. 8 weeks

Declining recovery, sleep fragmentation, tissue fragility. Resistance training mandatory.

Vol 2 Ch.15 p.117

Longevity Class III — immune-resilient

• TA-1 1.6 mg 2×/week
• KPV 200 mcg/day

Duration. 8 weeks + 4–6 week washout

Inflammatory aging, immune volatility. No repair peptides until immune noise falls.

Vol 2 Ch.15 p.117

Longevity Class IV — metabolic

• GLP-1 0.25–0.5 mg weekly (example class dose)
• CJC-1295 100 mcg pre-sleep
• Ipamorelin 100 mcg pre-sleep

Duration. 12 weeks

Visceral fat, insulin resistance. Protein ≥1.6 g/kg, lifting mandatory, no starvation. Weight loss is not the stated objective — metabolic clarity is.

Vol 2 Ch.15 p.118

Longevity Class V — advanced (disciplined only)

• BPC-157 250 mcg/day
• TB-500 2 mg/week
• TA-1 1.6 mg 2×/week
• CJC-1295 100 mcg pre-sleep
• Ipamorelin 100 mcg pre-sleep

Duration. 8 weeks + 6 week washout

Only when foundations are stable. Do not extend. Do not escalate.

Vol 2 Ch.15 p.118

Mitochondrial foundations (Vol 2 — before peptides)

• Sleep first — Vol 2: poor sleep means poor GH and poor repair, whatever the dose
• Protein ≥ 1.6 g/kg when metabolic peptides are in play (Vol 2)
• Resistance training in longevity Class II / IV
• Quiet inflammation (Class I: BPC-157 + KPV) before GH or immune stimulation
• MOTS-c / SS-31 / NAD have no ISSCA milligram table here — a clinician can discuss them after foundations
• ISSCA synergies magazine: NAD+ / glutathione IVs, HBOT, PEMF are clinic adjuncts — not a chat recipe

Duration. Ongoing — peptides still cycle 6–8 or 8–12 weeks with washout

Someone asks for a ‘mito stack’ or ‘anti-aging everything’. Sequence beats addition. If benefits vanish in washout, the protocol compensated rather than restored (Vol 2 Ch.15).

Vol 2 Ch.15 pp.117–118

Magazine longevity stack (Lapeire)

• Epitalon 5–10 mg SC daily × 10–20 days, 1–2×/year
• BPC-157 400–600 mcg SC daily
• TB-500 300 mcg–1 mg SC
• GHK-Cu daily injection or topical (magazine: both if accessible)
• Tesamorelin 500–2,000 mcg SC daily (fasted) — Vol 1 arsenal also lists 2 mg nightly for VAT; print both
• Ipamorelin 100–300 mcg SC daily (fasted)
• Humanin 0.04 mg/kg (~3.2 mg SC for an 80 kg adult) — magazine faculty, not a Vol 1/2 table

Duration. 10–20 day Epitalon core; other peptides daily in that window; 1–2× per year

Longevity / vitality questions after foundations (sleep, protein, zone-2). Faculty magazine, not a personal plan. Lifestyle first — ISSCA slide deck: do not sell peptides as magic.

ISSCA Peptides Magazine pp.7–10

Magazine neuro stack (Navarro)

• N-Acetyl Selank 100–300 mcg SC or 750–1,000 mcg IN; 6 weeks on / 6 off
• BPC-157 400–600 mcg SC
• TB-500 300 mcg–1 mg SC
• PE-22-28 400 mcg IN
• FGL(L) 1–2 mg SC
• Tesamorelin 500–2,000 mcg SC + Ipamorelin 100–300 mcg SC, fasted
• Dihexa 10–15 mg oral or topical; magazine: 3×/week, start low (half-life 7–10 days)
• Cerebrolysin 5–10 ml SC (215 mg/ml)

Duration. 6 weeks on / 6 weeks off; morning preferred; GH peptides fasted

Brain fog, burnout, concussion-adjacent literacy — after emergency/TBI care is ruled out. Not a DIY Alzheimer’s protocol.

ISSCA Peptides Magazine pp.11–15

Magazine beauty stack (Kushmiran)

• Tesamorelin 500–2,000 mcg SC daily (fasted)
• Ipamorelin 100–300 mcg SC daily (fasted); magazine 5 days on / 2 off × 10–12 weeks
• GHK-Cu 1–2 mg SC daily, 6-week cycles, 3–4×/year + topical after shower / microneedling
• PTD-DBM scalp spray 1–2×/week (0.001%)
• BPC-157 300–600 mcg SC 3–5×/week
• TB-4 300–1,000 mcg SC 3–5×/week; 10–12 weeks then 4–8 weeks off

Duration. GH peptides 10–12 weeks (5 on / 2 off); GHK-Cu 6-week pulses; BPC/TB 10–12 weeks

Glow / tighter skin / hair-quality questions. Sequence foundations first. People do stack — a clinician combines them.

ISSCA Peptides Magazine pp.17–20

Magazine regenerative terrain (synergies issue)

• No single biologic is enough — terrain first (ISSCA founder letter)
• Sleep, protein, zone-2 remain Volume 2 mitochondrial foundations
• Clinic adjuncts discussed: TPE, EBOO, HBOT, PEMF / red light / cryotherapy
• NAD+ and glutathione IVs as mitochondrial support around cell therapy — no milligram drip recipe in this library
• Bioidentical hormones and methylation testing are clinician tools, not chat protocols

Duration. Ongoing clinic architecture — not a peptide cycle

Someone asks for NAD drips, HBOT, ozone, or ‘the full regen stack.’ Sequence and refer; do not DIY extracorporeal procedures.

ISSCA Regenerative Synergies Magazine